Gilead Sciences’ (NASDAQ:GILD) announced $21B takeout of Immunomedics (NASDAQ:IMMU), a developer of therapeutic antibodies, including antibody-drug conjugates (ADCs), has stoked premarket action in fellow ADC players Seattle Genetics (NASDAQ:SGEN) (+9%) and Mersana Therapeutics (NASDAQ:MRSN) (+17%), both on light volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.